Project Grant R01DA063716
Award Date 8/15/26
Completion Date 6/30/31
Dollars Obligated $685K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $426,938 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate whether astrocyte elevated gene-1 (AEG-1) functions as an endogenous anti-opioid regulator that could improve the safety and efficacy of opioid analgesics. The research examines AEG-1's role in regulating morphine antinociceptive tolerance through peripheral neuronal sensory neuroinflammatory mechanisms. The...
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $177,216 on January 11, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on muscarinic receptor modulation as a pharmacological approach to stimulant use disorder. The project, titled "Muscarinic Receptor Mediation of Cocaine-Dependent Reward Signals: Impact of Pharmacological Modulation," investigates how M1 and M4 muscarinic acetylcholine receptor subtypes...
- The National Institute on Drug Abuse awarded The Regents of the University of California, San Francisco $200,880 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the spatiotemporal dynamics of G protein signaling by opioid receptors. The research investigates how mu-opioid receptors trigger cellular signaling pathways across multiple subcellular compartments, particularly endosomes, to advance understanding of opioid function relevant to...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $661,299 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research into opioid use disorder mechanisms and potential therapeutic targets. The research, titled "A Novel Cellular and Circuit Target for Opioids," investigates a transcriptionally distinct neuronal population in the nucleus accumbens that expresses high levels of the mu opioid receptor...
- The National Institute on Drug Abuse awarded Drexel University $832,132 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate novel circuit mechanisms underlying opioid-induced dopamine elevations in the nucleus accumbens, operating beyond the canonical midbrain dopamine neuron pathway. The research explores how oxycodone enhances dopamine signals through local circuits in the nucleus accumbens, specifically examining the role of GABA and cholinergic...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $210,168 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research dissecting glutamatergic pathway-specific ensembles guiding motivated behavior in opioid use disorder. The recipient will conduct basic neuroscience research investigating how opioids engage and adapt glutamatergic circuit elements to promote reward-driven behavior and habitual heroin use. The work...
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $1,182,810 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 15, 2026, to identify and characterize non-nicotine compounds in electronic nicotine delivery systems that drive abuse liability through functional activity at nicotinic acetylcholine receptor subtypes. The award funds high-throughput screening methods to comprehensively identify pharmacologically active non-nicotine constituents in...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $198,164 on September 25, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research examining delta opioid receptor regulation of parvalbumin interneuron transmission and oxycodone-related behavior. The project investigates how delta opioid receptor signaling in parvalbumin-expressing GABAergic interneurons within the prefrontal cortex contributes to opioid use disorder symptoms,...
- The National Institute on Drug Abuse awarded Virginia Commonwealth University $426,938 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026, to conduct a head-to-head preclinical comparison of how buprenorphine and methadone differentially impact cognitive outcomes and neuropathology in people with HIV. The project uses the EcoHIV mouse model to evaluate the effects of buprenorphine and methadone on cognitive performance and multiple indicators of neuropathology,...
- The National Institute on Drug Abuse (NIDA), within the Department of Health and Human Services, awarded Massachusetts General Hospital $451,670 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support final preclinical evaluation of a positron emission tomography neuroimaging probe for measuring mu opioid receptor density and occupancy in the human brain. The award funds development and validation of 18F-fluorocarfentanil (18F-FCFN) derivatives as safe,...